BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Here we present an Au-nanoprobe based approach for the molecular recognition and quantification of BCR-ABL b3a2 (e14a2) fusion for the early diagnosis of CML, which is inexpensive very easy to perform and uses total human RNA as target without reverse transcription and/or amplification.